Polyplus-transfection and Blue Sky BioServices sign a research and commercial license agreement for use of PEI-based transfection technologies

03-Nov-2014 - France

Polyplus-transfection SA and Blue Sky BioServices announced a non-exclusive, research and commercial license agreement. Polyplus has granted Blue Sky BioServices a licence to use Polyethylenimine (PEI) for in vitro transfection applications.

Blue Sky BioServices, has become the 17th sub-licensee, and the 4th CRO to acquire rights from Polyplus to use its PEI-mediated transfection applications for research and commercial purposes. Financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances